In line with this, FAK signaling to PI3K/AKT has already been reported [25,28], and indicates that AKT is a plausible target of FAK inhibition, especially for survival of FAK-copy-gain breast cancer cells. The gene discussed is AKT1; the disease is breast carcinoma.